Comparative analysis of tetanus Antitoxin titers of sera from Immunized guinea pigs determined by Toxin neutralization test and enzyme linked Immunosorbent assay by 26073821, -
COMPARATIVE ANALYSIS OF TETANUS 
ANTITOXIN TITERS OF SERA FROM 
IMMUNIZED GUINEA PIGS DETERMINED BY 
TOXIN NEUTRALIZATION TEST AND ENZYME-
LINKED IMMUNOSORBENT ASSAY 
 
A Dissertation Submitted to 
THE TAMILNADU DR. M.G.R. MEDICAL UNIVERSITY, CHENNAI 
In Partial fulfillment of the requirement for the 
Award of the Degree of 
 
MASTER OF PHARMACY 
(PHARMACEUTICAL BIO-TECHNOLOGY) 
 
Submitted by 
                                                       Reg. No: 26073821 
 
Under the guidance of 
Mr. T. SARAVANAN , M. Pharm 
Assistant Professor, Department of Pharmaceutical Bio-technology, 
 
NANDHA COLLEGE OF PHARMACY, 
PERUNDURAI ROAD, 
ERODE- 638052. 
MARCH – 2009 
 
 
  
                                                                                                                                        Introduction 
 
 
 
1 
INTRODUCTION 
 The toxin neutralization(TN) test in mice is a highly sensitive, reproducible 
and accurate technique for measuring tetanus antitoxin in sera. However ,the test is 
cumbersome, requiring large number of laboratory animals active and stable tetanus 
toxin. Well trained staff and relatively large volumes of sera. Therefore, several in 
vitro serological tests for titration of tetanus antitoxin have been developed.  
 Although in vitro tests such as indirect haemagglutination,
9,12
 several version 
of Enzyme linked immunosorbent assay (ELISA)
3,4,5,29,32,33
 and Toxin binding 
inhibition test
13
 have been widely used in many laboratories. None of these has been 
universally accepted as a substitute for the TN test.  
 ELISA has been widely recent years for titration of tetanus diphtheria 
antitoxins in human and animals sera due to simplicity, ease of automation, 
availability of stable reagents and objective interpretation. Different groups assign 
antibody concentrations by different methods including titers, international or 
antitoxin units (IU or AU)
3,4,5,27,32,33
 and weight based units µg / ml.
30 
 In most reports, ELISA results have not been directly compared with TN  in 
mice results  making a comparison of ELISA results from various laboratories 
extremely difficult. In the present study tetanus antibody levels in sera of immunized 
mice and guinea pigs were measured by ELISA at different intervals after 
immunization and correlated with TN titers 
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HISTORY OF TETANUS 
 Tetanus still causes almost 180,000 neonatal deaths and 10,000 to 30,000 
maternal deaths globally every year in developing countries, mostly in areas where 
access to clean deliveries and other health services is limited
 
. 
 In 1989, the World Health Assembly called for the elimination of neonatal-
tetanus, defined by WHO as less than one case of neonatal-tetanus per 1000 live 
births in every district of every countries
 
.
22
  
 In response, the maternal and neonatal tetanus (MNT) elimination initiative 
was launched in January 1999, with a goal to eliminate the disease globally by 2005. 
A strategy document was published by UNICEF/WHO/UNFPA in 2000, in which the 
agreed goal of MNT elimination would be achieved by reaching all child-bearing age 
women at high risk for tetanus with tetanus toxoid vaccine by 2005.
34
  
 About 30% of people with tetanus die from the infection. The risk of deaths is 
greatest in those over age 50. Neonatal-tetanus is a form of tetanus that occurs in 
newborn infants. Neonatal-tetanus is common in some developing countries. It causes 
more than 270,000 deaths worldwide per year .
28
 
1.1. TETANUS 
 Tetanus is caused by highly potent neurotoxin “tetanospasmin” produced by 
anaerobic condition of growth of Clostridium tetani. This bacterium is resistant to 
heat and disinfectantion. The end spores of clostridium tetani are commonly found in 
hospital environments, in soil and dust, and in the feces of many farm animals and 
humans. 
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 Clostridium tetani has 0.3 to 0.5µm in width and 2 to 2.5 µm in length. 
Clostridium tetani is a strict anaerobic and usually cultivated in McIntosh and fildes’ 
jar at optimum temperature of 37° C, the range of growth being 14º C to 48° C. it 
requires 3 to 4 days for good growth.
25
  
 The spore formation commences within 2 days at 37° C. The spores can 
withstand boiling for 40 to 60 minutes. When the moist heat is applied, the spores are 
killed at 105ºC at 25 minutes and 120°C in 20 minutes. They are killed by 5% phenol 
and watery solution of iodine or hydrogen peroxide kill the spores in few hours.  
1.2. PATHOGENESIS: 
The clostridium tetani produces two types of toxins 
 Tetanospasmin 
 Tetanolysin 
Tetanospasmin: 
 The clostridium tetani usually enters the body through open wound. The 
anaerobic conditions allow germination of spores and production of toxins. The toxin 
(tetanospasmin) binds in central nerve system. Toxin (tetanospasmin) interferes with 
neurotransmitter (Gamma-amino butyric acid) release to block inhibitory impulses. 
This leads to unopposed muscle contraction and spasm. 
Tetanolysin: 
 It is responsible for haemolysis seen on blood agar plates. It is active only in 
the reduced form that is under anaerobic condition and therefore termed 
“oxygenlabile”. 
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1.3. TYPES OF TETANUS:     
Local tetanus: 
          This is a rare and mild form of the disease. Local tetanus is characterized by 
persistent contraction of muscle in the same anatomic area as the injury, and may 
persist for several weeks before gradually subsiding. 
Cephalic tetanus: 
        It is a particular form of generalized tetanus, occurring when the tetanus spores 
enter through the middle ear, following middle ear infection or a head injury.  
Generalized tetanus: 
     It accounts for about 80% cases worldwide. After a period of general malaise 
Trismus (also knows as lockjaw) develops; this is characterized by spasm of the facial 
muscles. Stiffness of the neck, difficulty in swallowing, autonomic dysfunction is 
seen with the temperature rising between 2º C to 4° C above normal, elevated blood 
pressure, and rapid heart beat.  
Neonatal-tetanus: 
     Neonatal tetanus is a form of tetanus that occurs in newborn infants, most often 
through the use of the unsterilized cutting instruments on the umbilical (unhealed) 
stump. These babies usually have no temporary immunity passed from mother 
because their mother has not been vaccinated with Tetanus toxoid.
28
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1.4. INCUBATION PERIOD: 
     The incubation period varies from 3-21 days with an average of eight days. The 
further the injury site from central nervous system, the longer incubation period. The 
shorter  the incubation period, the higher risk of death (vaccine information.org, 
2003). 
1.5. TETANUS TOXOID: 
     Tetanus toxoid consists of a formaldehyde treated toxin. Used in EPI for 
immunizing pregnant mother. There are two types of toxoid available- adsorbed 
(aluminum salt precipitated) and fluid toxoids. 
 The adsorbed toxoid is preferred, because the antitoxin response reaches 
higher titers and long lasting. Tetanus toxoid is available as a single antigen 
preparation, or combined with diphtheria as paediatric DT or adult Td and with both 
diphtheria toxoid and acellular pertussis vaccine as DPT . 
 Children younger than 7 years of age should receive either DtaP or pediatric 
DT. Persons 7 years of age or older should receive the adult formulation. 
1.6. VACCINATION SCHEDULE AND USE:  
          DOSE           AGE        INTERVALS 
Primary-1      2-months        - - - - 
Primary-2      4-months      4-Weeks 
Primary-3      6-months      4-Weeks 
Primary-4      15-months      6-Months 
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Children WHO Receive DT: 
 The number of doses of DT needed to complete the series depends on the 
child’s age at the first dose. If first dose given at > 12 months of age 4 doses are 
needed. If first dose given at > 12 months 3 doses are needed. 
Routine DtaP Schedule children < 7 years of age: 
Booster Doses: 
         4-6 years, before entering school, 
         11-12 years of age, if 5 years since last dose, 
          Every 10 years thereafter.  
Routine DT Schedule Unvaccinated Persons > 7 years of age:    
                  Dose                Interval 
 Primary-1   - - - - 
 Primary-2  4 weeks 
 Primary-3  6-12 weeks 
DRUG DESCRIPTION 
 Tetanus Toxoid Adsorbed , for intramuscular use, is a sterile suspension of 
alum-precipitated (aluminum potassium sulfate) toxoid in an isotonic sodium chloride 
solution containing sodium phosphate buffer to control pH. The vaccine, after 
shaking, is a turbid liquid, whitish-gray in color 
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PREPARATION OF TETANUS TOXOID   
             Clostridium tetani culture is grown in a peptone-based medium and detoxified 
with formaldehyde. The detoxified material is then purified by serial ammonium 
sulfate fractionation, followed by sterile filtration, and the toxoid is adsorbed to 
aluminum potassium sulfate (alum). The adsorbed toxoid is diluted with physiological 
saline solution (0.85%) and thiomersal (a mercury derivative) is added to a final 
concentration of 1:10,000. 
 Each 0.5 mL dose is formulated to contain 5 Lf (flocculation units) of tetanus 
toxoid and not more than 0.25 mg of aluminum. The residual formaldehyde content, 
by assay, is less than 0.02%. The tetanus toxoid induces at least 2 units of antitoxin 
per mL in the guinea pig potency test. 
INDICATIONS 
 Tetanus Toxoid Adsorbed vaccine is indicated for active immunization of 
children 7 years of age or older, and adults, against tetanus, wherever combined 
antigen preparations are not indicated. 
 This vaccine should not be used for immunizing children below 7 years of 
age. In children below 7 years of age, either Diphtheria and Tetanus Toxoids and 
Acellular Pertussis Vaccine Adsorbed (DTaP) – Tripedia®, or Diphtheria and Tetanus 
Toxoids and Pertussis Vaccine Adsorbed USP (For Pediatric Use) (DTP) is 
recommended. If a contraindication to pertussis immunization exists, the 
recommended vaccine is Diphtheria and Tetanus Toxoids Adsorbed (For Pediatric 
Use) (DT).
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 For the prevention of neonatal tetanus in infants born of unvaccinated 
pregnant women, see Pregnancy section.
 
 This vaccine is NOT to be used for the treatment of tetanus infection. Only for 
prevention of tetanus. 
 As with any vaccine, vaccination with Tetanus Toxoid Adsorbed may not 
protect 100% of susceptible individuals. 
 If passive immunization is required, Tetanus Immune Globulin (Human) 
(TIG) should be used . 
DOSAGE AND ADMINISTRATION 
 Parenteral drug products should be inspected visually for extraneous 
particulate matter and/or discoloration prior to administration whenever solution and 
container permit. If these conditions exist, the vaccine should not be administered. 
 SHAKE VIAL WELL before withdrawing each dose. Discard vial of 
vaccine if it cannot be resuspended. 
 Inject intramuscularly in the area of the vastus lateralis (mid-thigh laterally) or 
deltoid. The vaccine should not be injected into the gluteal area or areas where there 
may be a major nerve trunk. 
 The following guidelines are derived from the Advisory Committee on 
Immunization Practices (ACIP). 
Primary Immunization for Persons 7 Years of Age and Older 
 A series of three doses of 0.5 mL each, of Tetanus Toxoid Adsorbed vaccine 
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should be given intramuscularly; the second dose of 0.5 mL is given 4 to 8 weeks 
after the first dose; and the third dose of 0.5 mL is given 6 to 12 months after the 
second dose. 
 Children who remain incompletely immunized after their seventh birthday 
should be counted as having prior exposure to tetanus and diphtheria toxoids (e.g., a 
child who previously received two doses of DTaP or DTP needs only one dose of 
Tetanus Toxoid Adsorbed vaccine to complete the primary series for tetanus. 
 Interruption of the recommended schedule with a delay between doses does 
not interfere with the final immunity achieved with Tetanus Toxoid Adsorbed 
vaccine. There is no need to start the series over again, regardless of the time elapsed 
between doses. 
Routine Booster Injections 
To maintain adequate protection, a booster dose of 0.5 mL of Td (For Adult Use) 
vaccine or Tetanus Toxoid Adsorbed vaccine every 10 years thereafter is 
recommended. 
Booster Injection After Injury 
 A thorough attempt must be made to determine whether a patient has 
completed primary immunization. Patients with unknown or uncertain previous 
immunization histories should be considered to have no previous tetanus toxoid doses. 
Persons who had military service since 1941 can be considered to have received at 
least one dose. Although most people in the military since 1941 may have completed 
a primary series of tetanus toxoid, this cannot be assumed for each individual. Patients 
who have not completed a primary series may require tetanus toxoid and passive 
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immunization at the time of wound cleaning and debridement. 
 
 Available evidence indicates that complete primary vaccination with tetanus 
toxoid provides long-lasting protection  10 years for most recipients. Consequently, 
after complete primary tetanus vaccination, boosters, even for wound management, 
need to be given only every 10 years when wounds are minor and uncontaminated. 
For other wounds, a booster is appropriate if the patient has not received tetanus 
toxoid within the preceding five years. Persons who have received at least two doses 
of tetanus toxoid develop antitoxin antibodies. 
 Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (Td) is the preferred 
vaccine for active tetanus immunization in wound management of patients  7 years 
of age. Because a large proportion of adults are susceptible to diphtheria, this vaccine 
enhances diphtheria protection. Thus, by taking advantage of acute health-care visits, 
such as for wound management, some patients can be protected who otherwise would 
remain susceptible. For inadequately vaccinated patients of all ages, completion of 
primary vaccination at the time of discharge or at follow-up visits should be ensured. 
 If passive immunization for tetanus is needed, TIG (Human) is the product of 
choice. It provides longer protection than antitoxin of animal origin and causes few 
adverse reactions. The currently recommended prophylactic dose of TIG (Human) for 
wounds of average severity is 250 units intramuscularly. When tetanus toxoid and 
TIG (Human) are given concurrently, separate syringes and separate sites should be 
used. The ACIP recommends the use of only adsorbed toxoid in this situation. 
Storage : Store between 2° – 8°C (35° – 46°F). DO NOT FREEZE.  
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NEUTRALISATION TESTS 
 Virus neutralization tests: Neutralization of virus by their antibodies can be 
demonstrated in various systems. Neutralization of bacteriophages can be 
demonstrated by the plaque inhibition test. When bacteriophages are selected in 
appropriate dilution on lawn cultures of susceptible bacteria, plaques of lysis are 
produced. Specific antiphage serum inhibits plaque formulation. Neutralization of 
animals, eggs and tissue culture. 
Toxin neutralization : 
 Bacterial exotoxins are good antigens and induce the formation of neutralizing 
antibodies (antitoxins) which are important clinically, in protection against and 
recovery from diseases such as diphtheria and tetanus. The toxicity of endotoxins is 
not neutralized by anti sera. 
 Toxin neutralization can be tested in vivo or in vitro. Neutralization tests in 
animals consist of injecting toxin – antitoxin mixtures and estimating the least amount 
of antitoxin that prevents death or disease in the animals. With the diphtheria toxin, 
which in small doses cause a cutaneous reaction, neutralization tests can be done on 
rabbit skin. The Schick test is based on the ability of circulating antitoxin to neutralise 
the diphtheria toxin given intradermally, and indicates immunity or susceptibility to 
the disease. Toxin neutralization in vitro depends on the inhibition of some 
demonstrable toxin effect. An example is the antistreptolysin O test, in which 
antitoxin present in patient sera neutralizes the hemolytic activity of the streptococcal 
O hemolysin. 
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ENZYME – LINKED IMMUNOSORBENT ASSAY 
History 
 Prior to the development of the EIA/ELISA, the only option for conducting an 
immunoassay was radioimmunoassay, a technique using radioactively-labeled 
antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal 
which indicates whether a specific antigen or antibody is present in the sample. 
Radioimmunoassay was first described in a paper by Rosalyn Sussman Yalow and 
Solomon Berson published in 1960. 
 
 Enzyme-Linked ImmunoSorbent Assay, also called ELISA, Enzyme 
ImmunoAssay or EIA, is a biochemical technique used mainly in immunology to 
detect the presence of an antibody or an antigen in a sample. The ELISA has been 
used as a diagnostic tool in medicine and plant pathology, as well as a quality control 
check in various industries. In simple terms, in ELISA an unknown amount of antigen 
is affixed to a surface, and then a specific antibody is washed over the surface so that 
it can bind to the antigen. This antibody is linked to an enzyme, and in the final step a 
substance is added that the enzyme can convert to some detectable signal. Thus in the 
case of fluorescence ELISA, when light of the appropriate wavelength is shone upon 
the sample, any antigen/antibody complexes will fluoresce so that the amount of 
antigen in the sample can be inferred through the magnitude of the fluorescence. 
 Performing an ELISA involves at least one antibody with specificity for a 
particular antigen. The sample with an unknown amount of antigen is immobilized on 
a solid support (usually a polystyrene microtiter plate) either non-specifically (via 
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adsorption to the surface) or specifically (via capture by another antibody specific to 
the same antigen, in a "sandwich" ELISA). After the antigen is immobilized the 
detection antibody is added, forming a complex with the antigen. The detection 
antibody can be covalently linked to an enzyme, or can itself be detected by a 
secondary antibody which is linked to an enzyme through bioconjugation. Between 
each step the plate is typically washed with a mild detergent solution to remove any 
proteins or antibodies that are not specifically bound. After the final wash step the 
plate is developed by adding an enzymatic substrate to produce a visible signal, which 
indicates the quantity of antigen in the sample. Older ELISAs utilize chromogenic 
substrates, though newer assays employ fluorogenic substrates enabling much higher 
sensitivity. 
TYPES 
INDIRECT ELISA 
  
  
 
 
 
 
 
Primary 
Anti body 
Secondary 
Anti body 
Substrate 
Antigen 
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The steps of the general, "indirect," ELISA for determining serum antibody 
concentrations are: 
1. Apply a sample of known antigen of known concentration to a surface, 
often the well of a microtiter plate. The antigen is fixed to the surface 
to render it immobile. Simple adsorption of the protein to the plastic 
surface is usually sufficient. These samples of known antigen 
concentrations will constitute a standard curve used to calculate 
antigen concentrations of unknown samples. Note that the antigen 
itself may be an antibody.  
2. A concentrated solution of non-interacting protein, such as bovine 
serum albumin (BSA) or casein, is added to all plate wells. This step is 
known as blocking, because the serum proteins block non-specific 
adsorption of other proteins to the plate.  
3. The plate wells or other surface are then coated with serum samples of 
unknown antigen concentration, diluted into the same buffer used for 
the antigen standards. Since antigen immobilization in this step is due 
to non-specific adsorption, it is important for the total protein 
concentration to be similar to that of the antigen standards.  
4. The plate is washed, and a detection antibody specific to the antigen of 
interest is applied to all plate wells. This antibody will only bind to 
immobilized antigen on the well surface, not to other serum proteins or 
the blocking proteins.  
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5. Secondary antibodies, which will bind to any remaining detection 
antibodies, are added to the wells. These secondary antibodies are 
conjugated to the substrate-specific enzyme. This step may be skipped 
if the detection antibody is conjugated to an enzyme.  
6. Wash the plate, so that excess unbound enzyme-antibody conjugates 
are removed.  
7. Apply a substrate which is converted by the enzyme to elicit a 
chromogenic or fluorogenic or electrochemical signal.  
8. View/quantify the result using a spectrophotometer, 
spectrofluorimeter, or other optical/electrochemical device.  
 The enzyme acts as an amplifier; even if only few enzyme-linked antibodies 
remain bound, the enzyme molecules will produce many signal molecules. A major 
disadvantage of the indirect ELISA is that the method of antigen immobilization is 
non-specific; any proteins in the sample will stick to the microtiter plate well, so small 
concentrations of analyte in serum must compete with other serum proteins when 
binding to the well surface. The sandwich ELISA provides a solution to this problem. 
 ELISA may be run in a qualitative or quantitative format. Qualitative results 
provide a simple positive or negative result for a sample. The cutoff between positive 
and negative is determined by the analyst and may be statistical. Two or three times 
the standard deviation is often used to distinguish positive and negative samples. In 
quantitative ELISA, the optical density or fluorescent units of the sample is 
interpolated into a standard curve, which is typically a serial dilution of the target.
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DIRECT ELISA 
 
 Direct ELISA is the most basic of ELISA configurations. It is used to detect 
an Ag (red triangle; virus/bacteria/fungus, recombinant peptide/protein, or another 
Ab) after it has been attached to the solid phase (e.g. a membrane or polystyrene 
microwell or dipstick).”An Ab (green), conjugated with a label (yellow star; e.g. 
HRPO, AP, FITC) is then incubated with the captured antigen. After washing off 
excess conjugate and incubating with a substrate and chromogen, the presence of an 
expected color indicates a specific Ab-Ag interaction. The conjugate could be a 
commercial preparation specific for the Ag of interest, or an in-house conjugated 
monoclonal or polyclonal Ab, or even patient serum. ”This format is identical to the 
Direct Fluorescent Assay (DFA) except this is performed on patient cells, usually 
with a glass slide as the solid phase and an FITC or TR conjugate. 
SANDWICH ELISA 
 
Antigen 
Antibody 
Substrate 
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 A sandwich ELISA. (1) Plate is coated with a capture antibody; (2) sample is 
added, and any antigen present binds to capture antibody; (3) detecting antibody is 
added, and binds to antigen; (4) enzyme-linked secondary antibody is added, and 
binds to detecting antibody; (5) substrate is added, and is converted by enzyme to 
detectable form. 
 A less-common variant of this technique, called "sandwich" ELISA, is used to 
detect sample antigen. The steps are as follows: 
1. Prepare a surface to which a known quantity of capture antibody is 
bound.  
2. Block any non specific binding sites on the surface.  
3. Apply the antigen-containing sample to the plate.  
4. Wash the plate, so that unbound antigen is removed.  
5. Apply primary antibodies that bind specifically to the antigen.  
6. Apply enzyme-linked secondary antibodies which are specific to the 
primary antibodies.  
7. Wash the plate, so that the unbound antibody-enzyme conjugates are 
removed.  
8. Apply a chemical which is converted by the enzyme into a color or 
fluorescent or electrochemical signal.  
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9. Measure the absorbance or fluorescence or electrochemical signal 
(e.g., current) of the plate wells to determine the presence and quantity 
of antigen.  
 The image to the right includes the use of a secondary antibody conjugated to 
an enzyme, though technically this is not necessary if the primary antibody is 
conjugated to an enzyme. However, use of a secondary-antibody conjugate avoids the 
expensive process of creating enzyme-linked antibodies for every antigen one might 
want to detect. By using an enzyme-linked antibody that binds the Fc region of other 
antibodies, this same enzyme-linked antibody can be used in a variety of situations. 
The major advantage of a sandwich ELISA is the ability to use crude or impure 
samples and still selectively bind any antigen that may be present. Without the first 
layer of "capture" antibody, any proteins in the sample (including serum proteins) 
may competitively adsorb to the plate surface, lowering the quantity of antigen 
immobilized. 
COMPETITIVE ELISA 
 A third use of ELISA is through competitive binding. The steps for this 
ELISA are somewhat different than the first two examples: 
1. Unlabeled antibody is incubated in the presence of its antigen.  
2. These bound antibody/antigen complexes are then added to an antigen 
coated well.  
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3. The plate is washed, so that unbound antibody is removed. (The more 
antigen in the sample, the less antibody will be able to bind to the antigen 
in the well, hence "competition.")  
4. The secondary antibody, specific to the primary antibody is added. This 
second antibody is coupled to the enzyme.  
5. A substrate is added, and remaining enzymes elicit a chromogenic or 
fluorescent signal.  
 For competitive ELISA, the higher the original antigen concentration, the 
weaker the eventual signal. 
 (Note that some competitive ELISA kits include enzyme-linked antigen rather 
than enzyme-linked antibody. The labeled antigen competes for primary antibody 
binding sites with your sample antigen (unlabeled). The more antigen in the sample, 
the less labeled antigen is retained in the well and the weaker the signal). 
ELISA REVERSE METHOD & DEVICE (ELISA-R M&D) 
 A newer technique uses a solid phase made up of an immunosorbent 
polystyrene rod with 4-12 protruding ogives. The entire device is immersed in a test 
tube containing the collected sample and the following steps (washing, incubation in 
conjugate and incubation in chromogenous) are carried out by dipping the ogives in 
microwells of standard microplates pre-filled with reagents. 
Advantages: 
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1. The gives can each be sensitized to a different reagent, allowing the 
simultaneous detection of different antibodies and different antigens for 
multi-target assays;  
2. The sample volume can be increased to improve the test sensitivity in 
clinical (saliva, urine), food (bulk milk, pooled eggs) and environmental 
(water) samples;  
3. One give is left unsensitized to measure the non-specific reactions of the 
sample;  
4. The use of laboratory supplies for dispensing sample aliquots, washing 
solution and reagents in microwells is not required, facilitating ready-to-
use lab-kits and on-site kits.  
APPLICATIONS 
 Because the ELISA can be performed to evaluate either the presence of 
antigen or the presence of antibody in a sample, it is a useful tool both for determining 
serum antibody concentrations (such as with the HIV test
[1]
 or West Nile Virus) and 
also for detecting the presence of antigen. It has also found applications in the food 
industry in detecting potential food allergens such as milk, peanuts, walnuts, almonds, 
and eggs.
[2]
 ELISA can also be used in toxicology as a rapid presumptive screen for 
certain classes of drugs. 
 The ELISA test, or the enzyme immunoassay (EIA), was the first screening 
test commonly employed for HIV. It has a high sensitivity. In an ELISA test, a 
person's serum is diluted 400-fold and applied to a plate to which HIV antigens have 
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been attached. If antibodies to HIV are present in the serum, they may bind to these 
HIV antigens. The plate is then washed to remove all other components of the serum. 
A specially prepared "secondary antibody" — an antibody that binds to other 
antibodies — is then applied to the plate, followed by another wash. This secondary 
antibody is chemically linked in advance to an enzyme. Thus the plate will contain 
enzyme in proportion to the amount of secondary antibody bound to the plate. A 
substrate for the enzyme is applied, and catalysis by the enzyme leads to a change in 
color or fluorescence. ELISA results are reported as a number; the most controversial 
aspect of this test is determining the "cut-off" point between a positive and negative 
result. 
 One method of determining a cut-off point is by comparison with a known 
standard. For example, if an ELISA test will be used in workplace drug screening, a 
cut-off concentration (e.g., 50 ng/mL of drug) will be established and a sample will be 
prepared that contains that concentration of analyte. Unknowns that generate a signal 
that is stronger than the known sample are called "positive"; those that generate 
weaker signal are called "negative." 
PRINCIPLE OF THE TEST  
 The Tetanus Toxoid IgG antibody test is based on the principle of the enzyme 
immuno assay (EIA). Tetanus antigen is bound on the surface of the microtiter strip. 
Diluted patient serum or ready- to- use standards are pipetted into the wells of the 
microtiter plate. A binding between the IgG antibodies of the serum and the 
immobilized Tetanus Toxoid antigen takes place. After a one hour incubation at room 
temperature, the plate is rinsed with diluted wash solution, in order to remove 
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unbound material. Then ready-to-use anti-human-IgG peroxidase conjugate is added 
and incubated for 30 minutes. After a further washing step, the substrate (TMB) 
solution is pipetted and incubated for 20 minutes, inducing the development of a blue 
in the wells. The color development is terminated by the addition of a stop solution, 
which changes the color from blue to yellow. The resulting dye is measured 
spectrophotometrically solution, which changes the color from blue to yellow. The 
resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The 
concentration of the IgG antibodies is directly proportional to the intensity of the 
color. 
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A 96-well microtiter plate being used for ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELISA reader 
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REVIEW OF LITERATURE 
 GREENBERG (1953)13 showed that the problem of assaying tetanus 
toxoids differs with the two test-animals used , the mouse and the 
guinea-pig. In the mouse, the slopes of dosage-response curves of plain 
and adsorbed toxoids are clearly not similar, so that separate standards 
are required for their assay. In the guinea-pig, the slopes of 
immunization curves for these two types are similar and one should 
suffice. While a second international standard for adsorbed 
preparations is not required, laboratories performing these tests are 
advised to establish separate standards- one for plain toxoids and one 
for adsorbed. 
 H. COHEN et al., (1959)21  This study showed  that the mouse is a 
very suitable laboratory animal for the comparison of adsorbed tetanus 
toxoids, and that an AIPO4- adsorbed vaccine, which is stable at 4
o
c, is 
a satisfactory reference preparation. The log-dose-response lines of 
toxoids adsorbed on different quantities of AIPO4 and on various 
quantities of another adsorbent ran parallel to those of the reference 
vaccine. The 95% confidence limits for the potencies of tetanus 
vaccines, diphetheria-tetanus vaccines, and eiptheria-pertussis-tetanus 
vaccines, determined by assay against the reference vaccine in mice, 
showed a high degree of reproducibility of the results. 
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 R MACLENNAN et al., (1965)22  Immunization of pregnant women 
in New Guinea with three injections of plain toxoid had previously 
been shown to prevent neonatal tetanus. In the present study antioxin 
levels induced by two oil-adjuvant toxoids (one injection), one AIPO4 
toxoid (two injections ) and one plain toxoid (three injections) were 
compared  with those induced by the same plain toxoid as used in the 
earlier study. At term there was no significant difference in the levels 
for the five toxoids, but those for the plain toxoids later declined 
rapidly. AIPO4-toxoid titres were significantly higher than the titres for 
the plain toxoids at the end of the year, but lower than the oil-adjuvant 
titres, which were the highest and most persistent. However, 
unacceptable side-effects (induced by subsequent lots of oil-adjuvant 
toxoids) preclude their routine use at present. The results indicate that a 
maternal antitoxin level at delivery of 0.01 unit/ml is protective. 
Aluminium-compound toxoid rapidly achieved titres that were better 
than this for at least a year, with minimal side-effects. Hence such 
toxoids are recommended for maternal immunization to prevent 
neonatal tetanus. 
 W. J. HERBRET  (1966)16 Comparative tests were done to find the 
best conditions under which formalinized sheep red cells can be tanned 
and then coated with chromatographically purified 
ovalbumin.Variation in the time taken for tanning or coating, the 
amount of antigen used, the temperature during coating, the use of 
different batches of tannic acid, ovalbumin or of cells formalinized by 
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different methods had little effect on sensitivity to agglutination by 
antibody A slight increase in sensitivity was obtained by coating at a 
low pH, by increasing the quantity of tannic acid employed and by heat 
denaturation of the antigen. 
 E. R. GOLD AND H. H. FUNDENBERG (1967)20 The passive 
hemagglutation procedure using a chromium chloride solution to bind 
antigens and antibodies to red cells has been investigated. The Crcl3 
method of coating red cells is rapid and simple, and serologic 
sensitivity and immunologic specificity are retained. The present 
studies showed that group O human red cells coated with antigen by 
the CrCl3 procedure can be used in a number of serologic reactions. In 
particular, use of CrCl3 treated cells as immunoadsobent provides a 
rapid method for the preparation of monospecific antisera to human  
immunoglobulins. The immunoglobulin content of pathologic sera can 
be estimated by the degree to which the pathologic seruminhibits an 
appropriate agglutination system consisting  of cells coated γG-, γA- or 
γM-globulin by the CrCl3 method and of homologous antibody. 
“Purified” immunoglobulin preparation can be assessed for 
contamination by similar inhibition of agglutination of red cells coated 
with immunoglobulins by the CrCl3 method. 
 ARTHUR A. HIRATA et al., (1968)17 Chicken, sheep and rabbit 
erythrocytes were stabilized with formaldehyde, pyruvic aldehyde or 
both, for use in passive hemagglutination reactions, Bovine serum 
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albumin, insoluble BSA, ovalbumin, rabbit γ-globulin, E. coli 
endotoxin, acetylated endotoxin, de-esterified endotoxin, de-esterified 
and bromacetylated endotoxin, succinylated endotoxin and synthetic 
polyglucose were found to absorb firmly on the stabilized cells. For 
optimal coating of stabilized cells with antigens, critical factors 
included pH, antigen concentration and the duration of contact with 
antigen. These conditions differed somewhat from one antigen to 
another.Antiglobulin tests wre applicable in all of the cases tested and 
were found to increase the hemagglutination titres 10- to 30- fold. 
 M.CAROLYN HARDEGREE et al., (1970)26 This paper  describes:  
1)a continuation of  the study reported in 1965 of tetanus antitoxin 
titres among women after primary immunization with plain, AlPO4 – 
adsorbed or oil adjuvant toxoids; (2) the effect of age and of abscess 
formation due to oil adjuvant on antitoxin response;. And (3) a 
comparative study of titres in some women of the study groups who 
received either a plain or an AlPO 4  Toxiod booster injection in 
pregnancy .  
 MICHAEL  F . BARILE  ET AL., (1970)27  The mouse toxin-
neutralization test procedure described has been used for antitoxin 
titration of sera of new Guinea women following primary 
immunization with plain and adjuvant tetanus toxoids and following 
booster immunization , and for titration of guinea –pig sera . The 
responses of guinea –pigs immunized with the same toxoids and 
immunization schedule to simulate the human field trial studies were 
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observed for 6 months . The relative antitoxin responses of guinea-pigs 
to the different toxoids were similar to those of the women . 
 M.CAROLYN HARDEGREE et al.,  (1970)28  Haemagglutination  (HA) 
has been used frequently for the titration of tetanus antitoxin but 
published results have varied in relation to the   “unitage”  determined 
by the mouse toxin –neutralization test (TH). This report gives the 
results of the titration of a group of sera by haemogglutination and 
compares them with the results obtained by toxin neutralization . 
Although there was marked variation between  HA  and TN titres of 
individual sera , results indicated that haemagglutination is a useful 
procedure for the over – all evaluation of the antitoxin responses to 
tetanus toxoids in field studies. 
 J.D.VAN RAMSHORST (1971)34   Available methods for titrating 
diphtheria and tetanus antitoxin at low concentrations in human or 
animal blood are surveyed, with special attention to the amount of 
serum required for the test .        In vivo methods, especially the rabbit 
or guinea-pigs international test for diphtheria and the mouse test for 
tetanus , are precise and reliable . If , however , serum levels as low as 
about 0.001IU/ml have to be determined, rather large amounts of 
serum are required ; moreover, the test  are rather time –consuming 
and expensive Tissue culture methods  are available only for diphtheria 
antitoxin titration . the titres found coincide very well with those form 
animal tests. The titrations are less time –consuming and more 
economical. These methods seem to be very  promising for the 
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replacement of animal tests. Of the real in vitro methods, the 
haemagglutinaton procedure has been investigated most thoroughly 
and used most frequently. Low titres can be measured using small 
amounts of serum , but the titres thus obtained may differ considerably 
from those obtained in animal tests ,at least for individual sera. For 
mass screening , the method is very suitable . 
 B.BYCENKO et al., (1971)35    Determination of the level of tetanus 
immunity in different age groups of a population is important in 
relation to the results of mass immunization of the population with 
vaccines  containing tetanus toxoid. In this study , the level of tetanus 
antitoxin in sera from 1053 inhabitants of 6 villages Bosnia and 
Herzegovina was determined by means of the passive 
haemagglutination test.the results show that children from 1to 14 years 
of age regularly immunized with DT and DPT vaccines possessed a 
high level of immunity against tetanus (geometric mean antitoxin titre 
=0.8 IU/ml) and were protected against tetanus in 80-95% of cases. 
The adult inhabitants(men and women over 29 years age)were not 
sufficiently protected against tetanus , the concentrations of antitoxin 
in their sera being equal to or greater then 0.01 IU/ml in less then 50% 
of cases. 
 K.W.NEWWELL ET AL., (1971)1       To Determine the 
effectiveness of a method for controlling tetanus neonatorum , a double 
–blind controlled trial involving 1618 women was conducted between 
1961 and 1966. women in the study were given 1-3 injections (1 ml ) 
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of aluminium –phosphate-adsorbed tetanus toxoid obtained from 299 
women . sera were titrated for anti-tetanus antibodies by two methods . 
A comparison of the clinical and laboratory results showed a close 
relationship. It is suggested that the level of protection may be lower 
then is at present accepted. Antitoxin levels were inversely related  to 
age and directly to the interval between injections . two widly spaced 
injections may be about as effective as 3 injections . one injection of 
specially prepared toxoid with a high immunizing potency might gives 
significant protection. 
 D. D. OURTH 5  (1977)18   This investigation found that the human 
antibody class of importance in neutralizing tetanus toxin in mice was 
IgG, and that toxin neutralization was retained by the F(ab’)2 and Fab’ 
subunits of the human IgG class. Although human IgM and IgA classes 
appeared to neutralize tetanus toxin at very low levels, evidence was 
obtained that this neutralization was probably due to IgG 
contamination. Human Fabµ, isolated from the IgM class did not 
neutralized tetanus toxoid in the indirect hemagglutination (HA) test 
with IgG giving the highest HA titre. Rabbit antibodies of the IgG 
class also neutralized tetanus toxin, with neutralization being retained 
by the F(ab’)2 and the Fab’ subunits of the rabbit IgG class. Absorption 
of several rabbit antisera to tetanus toxoid with goat-antirabbit Fc, 
which is specific for absorption of IgG from antiserum, rendered 
incapable of neutralizing tetanus toxin.  
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 MARGARET M. PEEL (1980)24 Variables affecting the indirect 
microhaemagglutination technique for measuring tetanus antitoion 
were investigated with a view to attaining maximum sensitivity in the 
test system by the application optimal conditions. The addition of 2-
mercaptoethanol to the diluent used for the preparaion  of  serial 
dilutions of antsera was also investigated as a simple means of 
inactivating the IgM component of tetanus antitoxin and so of 
improving the correlation between antitoxin titres determined by the 
indirect haemogglutination and by the toxin neutralization techniques. 
The use of mercaptoethanol in the assay system improved the 
correlation between titres determined by haemagglutinaton and T N 
test with same sera , but did not always reduce or eliminate the 
discrepancies. 
 MALATI KESKAR et al., (1981)19  Pre and postimmunisation 
samples of 189 medical students were simultaneously subjected to 
hemagglutination (HA) and toxin neutralization (TN) tests. HA method 
was found to be simple and economical but lacking in sensitivity and 
consistency. Refinement of the technique would be necessary before its 
application in the field on a mass scale. 
 MOIRA E.MELVILLE –SMITH et al.,(1983)5 An enzyme-linked 
immuniosorbent assay(ELISA) has been developed for the 
measurement of tetanus antitoxin in human sera as an alternative to the 
toxin neutralization test in mice, the currently accepted method of 
assay. The ELISA was found to be simple and quick to perform and 
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required only small amounts of materials. In addition, the assay was 
found to give reproducible estimates of antiroxin levels and to measure 
antitoxin at levels as low as 0.01 IU per ml, a sensitivity similar to tha 
of the neutralization test. Furthermore, a comparison of the results of 
the ELISA and the neutralization test involving 80 human sera, 
including sera with both high and low antitoxin levels, showed close 
agreement in antitoxin levels obtained by the two methods. It was 
concluded that ELISA was an acceptable alternative to the toxin 
neutralization test in mice for the measurement of tetanus antitoxin 
levels inhuman sera. 
 L.PITZURRA  et al.,(1983)6  Antibody titers to tetanus toxin in 
human sera were assayed by passive haemagglutination with turkey 
erythrocytes, enzyme-linked immunosorbent assay and 
counterimmunoelectrophoresis. The first two of these tests were shown 
to be the most sensitive for antibody detection, having the same range 
of sensitivity and reproducibility. The first two of these tests were 
shown to be the most sensitive for antibody detection, having the same 
range of sensitivity and reproducibility. The antibody levels 
determined by these assays were up to 400 fold higher than those 
determined by counterimmunoelectrophoresis. The turkey erythrocyte 
haemagglutination assay requires only 40 min, whereas the 
immunosorbent assay method requires 24 h. These results suggest that 
the haemagglutination assay is the more appropriate method for rapid 
and sensitive determination of tetanus antibody levels. 
  
Review of Literature 
 33
 R.K.GUPTA et al., (1983)14 Serum, samples from 77 guinea pigs 
immunized against tetanus have been titrated for tetanus antitoxin by a 
standardized indirect haemagglutination (IHA) test and the 
conventional toxin neutralization (TM) test. These sera were titrated 
before and after treatment of the sera with 2-mercaptoethanol(2-ME) 
by the IHA test using unfixed sheep erythrocytes and erythrocytes 
fixed with glutaraldehyde, formaldehyde and pyruvic aldehyde. The 
titres of these se5ra obtained by IHA using unfixed and 
glutaraldehyde-fixed sheep erythrocytes before treatment of the sera 
with 2-ME were two to six times higher than the TN titres, whereas the 
IHA titres using formaldehyde – and pyruvic aldehyde-fixed sheep 
erythorocytes were 10 times higher than the TN titres in some of the 
sera. There was no statistically significant difference between TN and 
IHA titres using unfixed and glutaraldehyde-fixed sheep erythrocytes 
after the treatment of the sera with 2-ME. 
 M.PITZURRA et al.,  (1983)11     Passive haemogglutination (HA) 
assays were performed using turkey red blood cells (TRBC-HA) on 
sera form normal healthy people , from normal people previously 
immunized against tetanus , and from tetanus patients receiving human 
using immunoglobulins. The TRBC-HA test was compared with HA 
assys using sheep red blood cells (SRBC-HA) and with the TN test 
,and was found to be more sensitive then the SRBC-HA test and 
showed good correlation with the TN test .  While the SRCB-HA assay 
calls for adsorption of sheep red blood cell agglutinins form the sera to 
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be tested , the use of turkey red blood cell does not requireany such 
adsorption. In addition, the TRBC-HA assy can be performed in 40 
minutes compared with 6 hours for the SRCB-HA assy. All these 
advantages make the TRBC-HA assy a more useful test for screening 
large numbers of sera in the evaluation of sera in the evaluation of 
tetanus immunity of normal people and of patients with wounds when 
seen in the emergency room of hospitals. 
 S.T.CHEN et al.,  (1983)23     A Study was undertaken to determine 
the relationship between the timing of maternal immunization with a 
commercially available adsorbed tetanus toxoid and the presence of 
protective antitoxin in cord blood. Women at various stage of gestation 
were given one or two doses of 20IU of toxoid, and the maternal and 
cord sera collected at delivery were assayed for tetanus antitoxin by the 
I HA and T N techniques. Results indicated that the first injection of a 
two –dose schedule should be given at least  60 days, and preferably 90 
days or more before delivery, with the second injection 20 days or 
more before delivery. The single-dose schedule conferred no 
significant 
 R.K.GUPTA et al., (1984)12 The tetanus antitoxin titres of 174 serum 
samples from healthy adults were determined by a standardized 
indirect haemagglutination test(IHA) and the conventional toxin 
neutralization (TN) test. The serum samples were titrated by the IHA 
test using glutaraldehyde-fixed and toxioid sensitized sheep 
erythrocytes before and after the treatment of the sera with 2-
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mercaptoethanol (2-ME). The IHA method  has been found to be very 
sensitive and specific for the estimation of tetanus antitoxin in human 
sera. The IHA titres before the treatment of the sera with 2-ME were 
generally about four times higher than the TN tires and the correlation 
coefficient between these titres was 0.94. The IHA titres after the 
treatment of the sera with 2-ME were in good agreement with the TN 
titres and there was no statistically significant differences between the 
titres by the two methods. The tetanus antitoxin titres of 50% of the 
sera were below the minimum protective titres of tetanus antitoxin 
(0.01 IU /ml). In 19.5% of the sera the antitoxin level (IU / ml) ranged 
from 0.01 to 0.1, in 20.1% from 0.1 to 1.0 and in 10.4% from 1.0 to 
10.0.  
 G.GENTILI  et al.,  [1984)32  A micro enzyme linked Immunosorbent 
assay has been adapted to the quantitation of Specific tetanus 
antibodies in commercial preparation pf human immunoglobulins.The 
results of the assay are compared with those obtained from the same 
samples tested by seroneutralisation tests invivo. Statistical analysis of 
the data shows good correlation between the titres obtained with two 
tests. Results obtained by indirect haemogglutination are also reported.  
It is proposed that all interested laboratories perform the described 
immuno enzymatic method invitro for a given period in parallel with 
the invitro test to gain sufficient experience of this technique  with the 
view to its to use as an alternative to invivo test 
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 GIULIANO GENTILI et al.,(1985)29 The ability of an enzyme-
linked immunosorbent assay (ELISA) to detect tetanus antitoxin in 
human sera has been evaluated in comparison with the in vivo 
seroneutralizationtest. The results of this study, carried out on 171 
serum samples, show that ELISA is a sensitive and specific in vitro test 
for immunity to tetanus in man; it reveals the minimum protective 
level of 0.01 IU /ml and is well correlated with seroneutralization. A 
comparison has also been made with indirect haemagglutination. 
Differences in specificity in low tittered sera, although not statistically 
significant, have been observed. Reported data suggest tha the ELISA 
may be used for the estimation of tetanus antitoxin in sero- 
epidemiological surveys and for clinical purposes with reliability 
equal-and perhaps superior- to that of IHA. 
 R.K. GUPTA et al.,(1985)9  The quality of retanus toxin affected the 
sensitivity  of the toxin neutralization(TN) test greatly. By using 
purified toxin a minimum level of 0.001 IU/ml only could be detected. 
The TN test described whereas with crude toxin a level of 0.025 IU/ml 
only could be detected. The TN test described in this report permitted 
titration of tetanus antitoxin in twofold dilution steps from levels as 
low as 0.001 IU/ml using 0.6 ml of serum only at the L+75000 level of 
purified tetanus toxin. Treatment of the sera with2-mercaptoethanol(2-
ME) did not affect the TN titres showing that the TN test detects the 
neutralizing antibodies (IgG) which are not affected by 2-ME. The TN 
test was found to be a highly sensitive and reproducible test. 
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 O.SIMONSEN et al., (1986)4 Serum samples form 727 persons with 
different vaccination histories were assessed for tetanus antitoxin 
content in an enzyme linked immunosorbent assay (ELISA) and tested 
for tetanus antitoxin neutralization activity in mice in order to compare 
the results obtained by the two methods. Neutralizing antibody 
activities in sera from individuals previously completely vaccinated 
correlated well with results obtained by ELISA and the accuracy 
increased with increasing antitoxin concentration in serum. This 
correlation was observed in sera from persons vaccinated recently as 
well as in sera from persons vaccinated many years ago. In sera from 
persons with an incomplete vaccination history ELISA was found to be 
an unreliable tool for the prediction of in vivo results. Many of these 
sera had antitoxin levels by ELISA far above the in vivo values, 
probably due to the presence of non specific or low avidity antitoxin 
which is detected in ELISA. 
 O.SIMONSEN et al., (1987)3  The use of indirect ELISA for the 
quantitation of tetanus toxin neutralizing antibodies in human sera is 
limited by marked overestimations in low tittered sera. The reasons for 
the discrepancy between the results obtained by ELISA and by in vivo 
assay and modifications of the ELISA to overcome the problem were 
investigated. Catching ELISA and indirect ELISA using trays coated 
with the contaminant proteins in toxoid preparations indicated that 
antibodies to contaminants were only partly responsible for the 
discrepancy and the introduction fo these modifications did not solve 
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the problem. In ELISA competiton experiments withtoxin neutralizing 
monoclonal antibodies, the human immunoglobulins irrelevant in toxin 
neutralization, byut detectable in indirect ELISA, were found to be 
difficult to inhibit  in their binding to the solid antigen phase. These 
might represent antitoxins bound bivalently to the solid phase but with 
affinities in monovalent binding isufficient for toxin neutralization or 
other coupled antibodies due to conformational changes of the antigen. 
 M.GERMAN-FATTAL et al., (1987)8  Immunity to tetanus was 
investigated in 157 individuals aged between 1 and 77 years using, for 
the evaluation of both tetanus antitoxin and antibody to fragment BIIb 
(anti-BIIb), an easily performed ELISA that gave reproducible results. 
Among these people 72% were protected against tetanus (tetanus 
antitoxin titres > 0.06IUml-1 (not protected against tetanus) were 
found to have anti-BIIb titres >0.15 Uml-1. These data raise questions 
as to the significance and protective effect of anti-BIIb against tetanus. 
 C.F.M HENDRIKSEN et al., (1988)15 A method for the screening of 
human sera for tetanus antibodies has been developed and evaluated. 
The toxin binding inhibition test(ToBI-test) is based on inhibition of 
the binding of tetanus toxin to an antitoxin- coated immunoassay 
microtitre plate by tetanus antibodies. Serum samples form 191 healthy 
adults with different vaccination histories have been titrated for teranus 
antibodies by the toxin neutralization (TN) test in mice, by toxoid-
ELISA and by the ToBi-test.  In every respect, the ToBI-test proved to 
be the best in vitro alternative to the TN-test in mice. Comparisons 
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showed a higher degree of correlation between the ToBI-test and the 
TN-test than between the toxoid-ELISA and the TN-test. Furthermore, 
no overestimation of antibody content was seen in titrating low titre 
sera by the ToBI-test. In contrast, several false positive results were 
seen when using the toxoid-ELISA. It is concluded that the ToBI-test 
is a reliable and precise alternative to the TN-test and can be performed 
under simple laboratory conditions in a short time. 
 INMACULADA ESPARZA AND THOMAS KISSEL (1992)25 The 
immunogenic potential of tetanus toxoid (TT) was compared when 
either adsorbed to aluminium hydroxide (TT-alum) or entrapped in 
microparticles consisting of  poly)D,L-lactic-CO-glycolic acid) (PLA: 
PGA, 55:45) derived polymers. Furthermore, the effect of 
administering the microparticles in an aqueous buffer or water-in-oil 
emulsion on the TT immunogencity was also investigated. When mice 
were immunized with the different formulations, similar levels of anti-
TT antibodies were observed during the primary IgG response. The 
choice of the carrier seemed to play an important role for both the level 
and maintenance of the secondary IgG response, attained as a 
consequence of a booster immunization with TT-containing 
microparticles, resuspended in wate-in-oil emulsions. As expected, 
incomplete Freund’s adjuvant (IFA) proved to be a more potent 
adjuvant than peanut oil, whereas resuspension of the microparticles in 
aqueous solution induced a relatively less efficient antibody response. 
Overall, microparticles in aqueous solution induced a more effectively, 
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since the secondary antibody response was higher and persisted longer 
compared with TT-alum priming. These results indicate that in 
addition to TT maintaining its antigenicity after microencapsulation, 
the microparticles also potentiate its immunogenic properties. This 
approach should prove very useful for designing more effective 
vaccines. 
 NILAY COPLU et al., (2004)7 In order to determine a pratically 
useful quantitative assay method for tetanus antibody in large-scale 
seroepidemiological study, a method combining an in-house ELISA 
with a particle agglutination test (KPA) was evaluated in comparison 
with the in vivo mouse neutralization test. Serum samples with mouse 
neutralization antibody titers 0.01 IU/ml (the minimum protective 
level) or below showed considerable over-estimation of antitoxin titers 
up to 1.0 IU/ml when studied by in –house ELISA alone. On the other 
hand, the DPA values were highly correlated with the mouse test, even 
in cases of titers equal to 0.01 IU/ml or below. The combination of 
these two procedures, in which in-house ELISA values of 1.01 IU/ml 
were replaced by KPA values, provided a high correlation in antibody 
titers with the mouse test (r=0.968). We applied this combined method 
to a tetanus seroepidemiological survey in a province in Turkey. The 
survey included347 subjects from the healthy population, and the 
qquantitative analyses showed high antibody levels in children and 
young adults and significantly low levels among adults aged 40 or 
over. A characteristic distribution of antibody titers in each age group 
was also demonstrated. 
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AIM AND OBJECTIVE 
The quality control testing of biologicals especially potency test is a subject on 
its own.  The biological standardizations of each procedure requires meticulous 
planning and execution.  The potency test for tetanus toxoid as specified in Indian 
pharmacopoeia is biological assay of tetanus antitoxin in immunized guinea pigs.  An 
in vitro serological assay system – ELISA to assess the potency of tetanus toxoid was 
standardized and results compared with the conventional biological assay. 
ELISA test has the advantages of easy automation and end point readings can 
be measured objectively. 
A major problem with ELISA is that different scientist assign antibody 
concentrations by different terminologies like AU/IU titers etc. 
 To determine the potency of tetanus toxoid by using ELISA was easy to 
perform, sensitive, highly reproducible and require only small quantities of sera and 
time saving.   
In the present study tetanus antibodies in sera of guinea pigs after 
immunization of 2 doses of tetanus toxoid were measured at a various methods by 
ELISA and compared with neutralization titres. 
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PLAN OF WORK 
1. Lf determination of tetanus toxoid by using flocculation method.  
2. Selection of test animals  guinea –pigs  
3. Immunization of guinea pigs  
4. Collection of blood and separation of sera  
5. Determination of potency 
5.1 Toxin neutralization test  
5.1.1. Tetanus anti toxin preparation  
5.1.2. Reference standard preparation 
5.1.3.  Test sera preparation 
5.1.3.1.. Neat sera preparation 
 5.1.3.2 Diluted sera preparation  
           5.2. ELISA  
                   5.2.1. Standardization of in-house ELISA for determination of ELISA IgG    
                              antibodies against TT raised in guinea pigs.  
                            a)Coating of antigen (TT) 
                            b)Preparation of reagents for conduct of ELISA  
                            c)Preparation of test protocols for standardization of 
• Antigen  
• Conjugate 
• Block buffer 
• Incubation times 
               5.2.2. Assessment Of IgG In Guinea-Pig Sera By ELISA 
                  5.2.3. Correlation between TN and ELISA  
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MATERIALS AND INSTRUMENTS 
1. Peroxidase conjugate  anti guinea 
pig IgG  
- SIGMA ALDRICH - USA 
2. Anhydrous sodium carbonate  - SD FINE –CHEM LTD.MUMBI 
3. Sodium hydrogen carbonate   - SD FINE –CHEM LTD.MUMBI 
4. Sodium chloride  - FLUKA  
5. Potassium dihydrogen phosphate   - SD FINE –CHEM LTD.MUMBI 
6. Disodium hydrogen phosphate 
dehydrate    
- MERCK –MUMBAI  
7. Potassium chloride  - NICE-CHEMICALS COCHIN   
8. Citric acid  - NICE-CHEMICALS COCHIN   
9. Sodium hydrogen  - NICE-CHEMICALS COCHIN   
10. Dried skimmed milk - BHARATH BIO CHEM LTD 
11. Polysorbate 20 - HI MEDIA  
12. Diammonium 2,2’-azinobis   - HI MEDIA  
13. Elisa plates  96 wells    -  NUNC  
14. Sodium citrate  - NICE CHEMICALS COCHIN   
15. Anti toxin  - CDL CRI  KASAULI 
16. T.T. adsorbed  - BETT   
17. Glycerin  -  QUALIGEN, MUMBAI  
18. Peptone  - HIMEDIA – MUMBAI  
19. Gloves  - DIAMOND GRIB PLUS  
20. Wells  - NUNC BRAND PRODUCTS 
DENMARK 
21. Disposable sterile pipette tips   - VWR 
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INSTRUMENTS USED 
S.No INSTRUMENTS NAME - COMPANY 
1. Auto clave - NEW LAB EQUIPMENT 
2. Centrifuge - REMI 
3. Deep Freezer - SIEMENS 
4. Digital P
H 
meter  - NEW LAB EQUIPMENT 
5. Hot air oven  - GENUINE 
6. Incubator - HERA CELL 150 
7. Laminar Air flow - GENUINE  
8. Refrigerator - LG 
9. Shaker   - NEW LAB EQUIPMENT 
10. Water bath - GENUINE 
11. Flocculation apparatus - KING INSTITUTE   
12. 5µl Pipette - STERILIN   
13. 10µl Pipette - FALCON  USA 
14. 100µl Pipette  - STERILIN   
15. 200-1000 µl Pipette - FALCON  USA 
16. Multi channel pipette   - CAPP-FRANCE 
17. Cryo tube vials -  NUNC 
18. ELISA Reader - LAB SYSTEM MULTISKAN EX 
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METHODOLOGY 
1.Lf DETERMINATION OF TETANUS TOXOID BY USING     
FLOCCULATION METHOD.
37
  
PROCEDURE 
Preparation of 10% tri Sodium Citrate Solution: 
   10.0g of tri sodium citrate was weighed and transferred in to the     
100 ml bottle and  the volume was maked to 100 ml using WFI /Miii Q water. Stored  
at room temperature for not more than 6 months. 
Test Procedure: 
 10 ml of the sample was taken in a 15 ml centrifuge tube. 
 Centrifuged  at 2000 rpm for 10 minutes. 
 Supernatant was collected in another tube and label it as supernatant. The 
supernatant contains Lf from the vaccine sample that was left unabsorbed. 
0Store at 2-8

C for testing at a later stage. 
 To the sediment of the test tube, labeled as Elute add 10% tri sodium citrate  
solution to make up the make up the volume to 10 ml. Incubated at 35-37

C 
for about 16 hours. Tetanus Toxoid shall elute in this mixture and is tested for 
Lf that is contributed by adsorbed tetanus toxoid in the sample. 
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  10 ml of the sample was taken in another test tube and label it as Total, add 
10.0 g of tri sodium citrate. Mixed well and incubated at 35-37°C for about 16 
hours. It contains total Lf contributed by both adsorbed as well as unadsorbed 
tetanus toxoid. 
  The Lf in supernatant was estimated  by performing the Lf test taking 
antitoxin concentration in the range of 2 Lf to 10 Lf with the difference of 1Lf. 
Add 0.85% sterile phgysiological saline was added  in the tubes to make up 
the volume to 1.0 ml. Add 1.0 ml of the supernatant sample to all flocculation 
tubes. 
 The Lf in Elute was estimated by performing the Lf with the difference of 1 
Lf. Add 0.85% sterile physiological saline in the tubes to make up the volume 
to 1.0 ml.  1.0 ml of the Total sample was added to all flocculation tubes. 
 Keep the reaction mixture at 45-50°C in water bath in such a way that at least 
half of the reaction mixture is in the water. 
 The tubes were observed for the flocculation reaction to occur. 
 Mixture flocculating first is that which contains the most nearly equivalent 
quantities of Tetanus Toxoid. 
2.SELECTION OF TEST ANIMALS ON GUINEA –PIGS
2
  
 Healthy guinea – pigs was used from the same stock and weighing between 250 
and 350 g. Distribute them into six groups of sixteen  each. The guinea – pigs should 
all be of the same sex or the males and females should be distributed equally between 
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the groups. if the challenge toxin to be used has not bee shown to  be stable or has not 
been adequately to serve as unvaccinated controls.    
3. IMMUNIZATION OF GUINEA PIGS 
2
 
Inject subcutaneously on each of two occasions separated by an interval of not 
more than weeks, one tenth of the stated human does diluted to 1 ml with saline 
solution into each of 9 normal, healthy  guinea – pigs weighing between 250 and    
350 g. Not more than 2 weeks after the second injection. collect the serum form each 
animal and carry out the biological test for tetanus antitoxin, described under Tetanus 
antitoxin or any other method approved by National Regulatory Authority.  
Animal used Guinea pig Hartley 
Weight range 250- 350 g 
No. of guinea pigs 12 
Dose 0.5ml 
Route of inoculation subcutaneous 
Date of 1
st
 dose 18.09.08 
Date of 2
nd
 dose 17.10.08 
Bleeding on 29.10.08 
Sera stored at 2 to 8
0
c 
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4. COLLECTION OF BLOOD AND SEPARATION OF SERUM 
Preparation of serum samples: For preparation of serum samples, the 
following  technique has been found suitable. Invert the tubes containing blood 
samples 6 times and allow to stand 37
0
c for 2 h, then 4
0
cfor 2 hours
 
, centrifuge at 
room temperature at 800 g for 20 min. transfer the serum to sterile tubes and store at a 
temperature below - 20
0
c. At least
 
40 % yield  of serum is obtained by this procedure.  
5.TOXIN NEUTRALIZATION TEST
37
 
5.1.1 TETANUS ANTI TOXIN PREPARATION 
 The 915 International Units Per Vial Tetanus Anti toxin (invivo) was mixed 
with 91.5 ml of normal saline (1 ml contain 10 units of AT) and from this solution   
0.1 ml was taken  and mixed with 19.9 ml of normal saline, This standard preparation 
contain 0.05 units/ml. 
5.1.2 REFERENCE STANDARD PREPARATION 
a. Low concentration of toxin preparation  (LCTP) 
The 0.225 ml of glycerinnated toxin was taken and made up with 50ml of 
peptone water. 
b.  Substantiated  concentration of toxin preparation  (SCTP) 
The 0.275 ml of glycerinnated toxin was taken and made up with 50ml of 
peptone water. 
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c. High concentration of toxin preparation  (HCTP) 
The 0.325 ml of glycerinnated toxin was taken and made up with 50 ml of 
peptone water. 
5.1.2.1 REFERENCE STANDARD PREPARATION 
1. Low concentration of  Reference standard preparation  
 The 0.6 ml of normal saline, 0.6 ml of LCTP was taken and 0.3 ml of anti 
toxin was added  
2. Substantiated  concentration of  Reference standard preparation  
 The 0.6 ml of normal saline, 0.6 ml of SCTP was taken and 0.3 ml of anti 
toxin was added  
3. High concentration of Reference standard preparation  
 The 0.6 ml of normal saline, 0.6 ml of HCTP was taken and 0.3 ml of anti 
toxin was added  
5.1.3 TEST SERA PREPARATION 
5.1.3.1 NEAT SERA PREPARATION  
 0.6 ml of normal saline, 0.6 ml of SCTP was taken in the test tube and 0.3 ml  
of guinea pig test sera was added. 
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5.1.3.2 DILUTED SERA PREPARATION  
 5.1.3.2.1 Sub Dilution sera preparation  
 Each test tube 0.9 ml of normal saline was taken and 0.1 ml of guinea pigs 
serum was added (This test sera was 10 times diluted.) 
 5.1.3.2.2 Diluted serum test preparation  
 The 0.6 ml of normal saline, 0.6 ml of SCTP was taked and 0.3 ml of SDSP 
solution was added. 
ANIMAL INOCULATION 
 Neat serum preparation and Diluted serum test preparation was stored in room 
temperature at one hour after one hour each test taken 0.5.ml was injected for two 
mice and observed the mice at four days. 
Animal Mice Swiss Albino 
Weight range 17 – 22 g 
Dose/mice 0.5 ml 
Route Subcutaneous 
No. of Mice/Dilution 2 mice 
Test Started on 30.10.08 
Observation Period 4 days 
Test Completed on 02.11.08 
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5.1 ELISA 
5.2.1 STANDARDIZATION OF IN HOUSE ELISA FOR DETERMINATION 
OF ELISA IgG ANTIBODIES AGAINST TT RAISED IN GUINEA PIGS. 
a) Coating of Antigen  
Tetanus toxoid coated 0.5 LF of commercial TT was coated and stored at 4
0
c 
for over night. 
      b) Preparation of reagents for conducting  ELISA 
    1) Peroxidase conjugate preparation  
Peroxidase conjugated rabbit or goat antibody directed against guinea 
– pig lgG 
2) Carbonate coating buffer pH 9.6  
Dissolve  1.59 g of  anhydrous sodium carbonate and 2.93g of sodium 
hydrogen carbonate  in 1000 ml of water. Distribute  into 150 ml bottles and 
sterilize by  autoclaving  at 121
0
c for 15 min  
3)Phosphate Buffered Saline Preparation PH7.4  
Dissolve with  stirring 80 g  of sodium chloride, 2.0 g of potassium 
dihydrogen phosphate, 14.3 g of disodium hydrogen phosphate dihydrate and 
2.0 g of  potassium  chloride  in 1000 ml of water. store at room temperature 
to event  crystallization. Dillute to 10 times its volume with water  before use.        
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4) Citric Acid Solution Preparation 
Dissolve 10.51g of citric in 1000 ml of water and adjust the solution to 
pH 4.0 with a 400g/l solution of sodium  hydroxide  
5) Washing Buffer Preparation  
  PBS containing 0.5g/l  of polysorbate 20 
6) Diluent block buffer preparation  
PBS containing 0.5 g/l of polysorbate 20 and 25g/l of dried skimmed 
milk.    
7)Peroxidase Substrate Preparation. 
Shortly before us. dissolve 10 mg of diammonium 2.2- azti bobis 93 
ethylebenzthizoline 6 sulphonate) (ABTS) in 20 ml citric and solution. 
Immediately before use add 5 µl if strong hydrogen peroxide solution  
 
c) Preparation of test protocols for standardization of 
• Antigen 
0.5 Lf, 1 Lf and 1.5 Lf  the three concentration of TT antigen is 
compared by performing Indirect ELISA assay . this varies antigen 
concentration assay were  performed by  inter- intra days 
• Conjugate ; (secondary antibody)     
                 1:2000, 1:10,000 , 1:15000 and 1:20000 , this four dilution of 
conjugates were compared and observed by inter and intra days 
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• Blocking buffers  
                    The two blocking buffers BSA , dried skimmed milk, was 
repeated thrice on the same day &also on different days  
• Incubation times   
                    Varying incubation times with blocking buffer were used 
 (1 & 2 hrs) was compared. 
 Standard Reference 
The guinea pigs sera showing more than 0.5 unit/ ml detected by Antibody 
titration method.(T N). The 6 guinea pigs sera was pooled. The sera was 
diluted with skimmed milk.  The peroxidase conjugate was diluted with 
skimmed milk 1:20,000 dilutions. The test performed as follows  
ELISA 96 WELL PLATE 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
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 The description below is given as an example of a suitable plate lay 
out- but others may be used. 
 Wells 1A- H are for negative control serum and wells 2 A- H AND 3 
A –H are for positive control serum for assay monitoring. 
  Wells 7-12 A-H are for test samples. 
  Each well of the ELISA Plates was coated with 100 µl of tetanus 
toxoid solution (0.5 Lf/ml in carbonate coating buffer). 
 Allowed to stand overnight at 40c in a  humid atmosphere.  
 To avoid interference from temperature gradient. did not stack more 
than 4 plates high  
 On the following day, wash the plates thoroughly with washing buffer. 
  The plates were blocked by addition of 100 µl of diluents block buffer 
to each well.  
   Incubated in a humid atmosphere at 37°c for 2 h.  
 Washed the plates thoroughly with washing buffer.  
  100 µl of diluent block buffer was placed in each well of the plates, 
except those of row A. 
  Suitable  of negative control serum, positive control serum (from 
about 0.01U/ml) and test sera were used.  
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 Allocated the negative control serum to column 1, positive control 
serum to columns 2 and 3 and test sera to columns 4-12 and add 100µl 
of each serum to the first 2 wells of the column to which it is allocated.   
 Incubated at 37° for 1 h. Wash thoroughly with washing buffer. 
  A suitable dilutions (a 1 in 20,000 dilutions has been found suitable) 
of peroxidase conjugate in diluent block buffer was prepared and 
added 100µl to each well.  Incubated at 37° in a humid atmosphere for 
30 min. Washed the plates thoroughly with washing buffer. 
  100 µl of peroxidase substrate was added to each well,. 
 Allowed to stand at room temperature, protected from light, for 10 
min. 
 And Stop solution was added   
 Read the plates at 450 nm in the same order as addition of substrate 
was made. 
5.2.2. ASSESSMENT OF IgG IN GUINEA-PIG SEEN BY ELISA. 
PROCEDURE  
 Each well of the ELSA Plates was coated with 100 µl of tetanus toxiod 
solution (0.5 Lf/ml in carbonate coating buffer). 
 Allowed to stand overnight at 40c in a  humid atmosphere.  
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 To avoid interference from temperature gradient. did not stack more 
than 4 plates high  
 On the following day, wash the plates thoroughly with washing buffer. 
  The plates were blocked by addition of 100 µl of diluents block buffer 
to each well.  
   Incubated in a humid atmosphere at 37°c for 2 h.  
 Washed the plates thoroughly with washing buffer.  
  100 µl of diluent block buffer was placed in each well of the plates, 
except those of row A. 
  Suitable  of negative control serum, positive control serum (from 
about 0.01U/ml) and test sera were used.  
 Allocated the negative control serum to column 1, positive control 
serum to columns 2 and 3 and test sera to columns 4-12 and add 100 µl 
of each serum to the first 2 wells of the column to which it is 
allocated..  
 Incubated at 37° for 1 h. Wash thoroughly with washing buffer. 
  A suitable dilutions (a 1 in 20,000 dilutions has been found suitable) 
of peroxidase conjugate in diluent block buffer was prepared and 
added 100 µl to each well.  Incubated at 37°c in a humid atmosphere 
for 30 min. Washed the plates thoroughly with washing buffer. 
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  100 µl of peroxidase substrate was added to each well,. 
 Allowed to stand at room temperature, protected from light, for 10 
min. 
 And Stop solution was added   
 Read the plates at 450 nm in the same order as addition of substrate 
was made. 
    5.2.3. CORRELATION BETWEEN TN AND ELISA 
 The Toxin neutralization test and ELISA was correlated by statistical methods. 
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RESULTS AND DISCUSSION 
ELISA specific antitetanus IgG antibodies appear in the sera of guinea pigs at 
42 days of immunization of 2 doses of tetanus toxoid.  The antibodies measured by 
conventional toxin neutralization test correlated well with Elisa. 
1. Lf determination of tetanus toxoid by using flocculation method.  
The tetanus toxoid LF was identified. 0.5 ml contain 5 LF commercial tetanus 
toxin was identified.  
2. Selection of test animals on guinea –pigs  
The guinea-pig was selected and used for the test weight 250-350g 
3. Immunization of guinea pigs  
The 12 guinea-pigs after TT injected and one control guinea-pigs the 
conditions was observed daily. 
Observation of Guinea Pigs 
Date 1 2 3 4 5 6 7 8 9 10 11 12 Control 
18.9.08 N N N N N N N N N N N N N 
19.9.08 N N N N N N N N N N N N N 
20.9.08 N N N N N N N N N N N N N 
21.9.08 N N N N N N N N N N N N N 
22.9.08 N N N N N N N N N N N N N 
23.9.08 N N N N N N N N N N N N N 
24.9.08 N N N N N N N N N N N N N 
25.9.08 N N N N N N N N N N N N N 
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26.9.08 N N N N N N N N N N N N N 
27.9.08 N N N N N N N N N N N N N 
28.9.08 N N N N N N N N N N N N N 
29.9.08 N N N N N N N N N N N N N 
30.9.08 N N N N N N N N N N N N N 
1.10.08 N N N N N N N N N N N N N 
2.10.08 N N N N N N N N N N N N N 
3.10.08 N N N N N N N N N N N N N 
4.10.08 N N N N N N N N N N N N N 
5.10.08 N N N N N N N N N N N N N 
6.10.08 N N N N N N N N N N N N N 
7.10.08 N N N N N N N N N N N N N 
8.10.08 N N N N N N N N N N N N N 
9.10.08 N N N N N N N N N N N N N 
10.10.08 N N N N N N N N N N N N N 
11.10.08 N N N N N N N N N N N N N 
12.10.08 N N N N N N N N N N N N N 
13.10.08 N N N N N N N N N N N N N 
14.10.08 N N N N N N N N N N N N N 
15.10.08 N N N N N N N N N N N N N 
16.10.08 N N N N N N N N N N N N N 
17.10.08 N N N N N N N N N N N N N 
18.10.08 N N N N N N N N N N N N N 
19.10.08 N N N N N N N N N N N N N 
20.10.08 N N N N N N N N N N N N N 
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21.10.08 N N N N N N N N N N N N N 
22.10.08 N N N N N N N N N N N N N 
23.10.08 N N N N N N N N N N N N N 
24.10.08 N N N N N N N N N N N N N 
25.10.08 N N N N N N N N N N N N N 
26.10.08 N N N N N N N N N N N N N 
27.10.08 N N N N N N N N N N N N N 
28.10.08 N N N N N N N N N N N N N 
N - NORMAL 
Discussion  
           The immunized guinea-pig were observed daily. All guinea-pig were normal 
and healthy. Food and water was provided daily &housed in a quiet environment.  
26.09.08 –  9
th
 day Bleeding by cardiac puncture under anaesthesia (ether) 
07.10.08 – 20
th
 day Bleeding by cardiac puncture under anaesthesia (ether) 
16.10.08 – 30
th
 day Bleeding by cardiac puncture under anaesthesia (ether) 
29.10.08 – 43
rd
  day Bleeding by cardiac puncture under anaesthesia (ether) 
4. Collection is blood and separation of serum  
The blood was collected and sera was separated stored at -20
o
C 
5. Determination of potency 
5.1 Toxin neutralization test  
SYMPTOMS IN MICE 
STAGES Normal  
I.  slight stiffness to hind limb + 
II.  cramping of hind limb with scoliosis ++ 
III.  serious cramping pronounced scoliosis +++ 
IV.  Death D 
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OBSERVATION REFERENCE STANDARD 
Observation Days / Date 
S.No. 
Unit age 
tested for 
(1U/ml) 
Mice 
1 2 3 4 
1  ++ D - 
1 
HC 
0.5ml 2  ++ D - 
1  ++ +++ D 
2 
SC  
0.5ml 2  ++ +++ D 
1     3 LC 
0.5ml 
2     
 
DISCUSSION 
 The dose neutralized mixture (normal saline+ toxin+ sera) injected mice was 
observed daily .  
1. HC dose should stage IV symptoms on 3th  day due to high level of 
toxin 
2. SC dose should stage IV on 4th days as the unitage of antitoxin is 
0.5IU/ml  . 
3. LC dose mice should stage I. 
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5.1.3.1 OBSERVATION OF NEAT TEST SERA: 
Observation Days / Date 
S.No. 
Unitage 
tested for 
(1U/ml) 
Mice 
1 2 3 4 
No 1     
1 Neat Sera 
No 2     
No 1     
2 Neat Sera 
No 2     
No 1     3 Neat Sera 
No 2     
No 1     4 Neat Sera 
No 2     
No 1     5 Neat Sera 
No 2     
No 1     6 Neat Sera 
No 2     
No 1     7 Neat Sera 
No 2     
No 1     8 Neat Sera 
No 2     
No 1     9 Neat Sera 
No 2     
No 1     10 Neat Sera 
No 2     
No 1     11 Neat Sera 
No 2     
No 1     12 Neat Sera 
No 2     
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DISCUSSION  
 The neat serum does injected mice four days normal condition. so neat sera 
contain 0.05 IU/ ml was detected. 
5.1.3.2 OBSERVATION OF DILUTED TEST SERA 
 
Observation Days / Date 
S.No. 
Unitage 
tested for 
(1U/ml) 
Mice 
1 2 3 4 
No 1     
1 
Diluted 
Sera 
No 2     
No 1     
2 
Diluted 
Sera 
No 2     
No 1     3 Diluted 
Sera 
No 2     
No 1     4 Diluted 
Sera 
No 2     
No 1     5 Diluted 
Sera 
No 2     
No 1     6 Diluted 
Sera 
No 2     
No 1     7 Diluted 
Sera 
No 2     
No 1     8 Diluted 
Sera 
No 2     
No 1     9 Diluted 
Sera 
No 2     
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No 1     10 Diluted 
Sera 
No 2     
No 1     11 Diluted 
Sera 
No 2     
No 1     12 Diluted 
Sera 
No 2     
 
DISCUSSION  
 The diluted sera does injected mice was four days normal condition. so diluted 
serum contain 0.5 IU/ml was conformed. 
5.2.1. Standardization of in-house Elisa for determination of Elisa IgG antibodies 
against TT raised in guinea pigs.  
c)Preparation of test protocols for standardization of 
 Antigen 
The interpretation  of optical density of values of ELISA assay showed that 
antigen at the concentration of 0.5 Lf was standard value , this values exhibits that 
antigen and antibodies titer are equal level .  
For the other concentration 1Lf, and 1.5Lf the OD values  varied. This was 
due to the high concentration of antigen and low antibody titers. Which resulted in 
partial binding of antigen & antibodies. . 
These varying antigen concentration assay were repeated thrice on the same 
day &also on different days &0.5Lf gave reproducible results.  Thus 0.5Lf was taken 
as the optimum concentration to detect TT antigen.      
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  Conjugate : (secondary antibody)              
The conjugates at the concentration of 1:2000,1:10000,1:15000 exhibited high 
intensity of color reactions after adding substrate. The conjugate of the concentration 
of 1:20000 showed properresult.  
Therefore 1:20000 concentration was standardized in detecting of TT      
antibodies. 
  Blocking buffers  
BSA blocking buffer was not effective in blocking of unwanted particles. This 
dried skimmed was found to be effective in blocking of unwanted particles in antigen 
coated wells. 
 Incubation times 
Varying  incubation times with block buffer were used (1&2hrs).it was found 
that blocking for 2hrs prevented non specific binding &resulted in OD values which 
were accurate &with less background effect. 
Table-1: Standard Curve Values 
S. 
No 
IU/ml OD values 
1. 0.005 1.480 
2. 0.01 1.560 
3. 0.25 2.000 
4. 0.5 2.44 
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5.2.2. Table-2 ASSESSMENT OF IgG IN GUINEA-PIG SEEN BY ELISA. 
No.of Guinea-pig sera  IU/ml OD values 
1. 0.525  2.4618 
2. 0.55 2.510 
3. 0.5 2.4410 
4. 0.51 2.4517 
5. 0.56 2.514 
6. 0.54 2.4912 
7. 0.55 2.524 
8. 0.45 2.314 
9. 0.53 2.488 
10. 0.56 2.538 
11. 0.565 2.548 
12. 0.572 2.555 
9
th
 day  0.0025 1.426 
20
th
 day 0.005 1.495 
30
th
 day 0.01 1.568 
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5.2.3CORRELATION BETWEEN TN AND ELISA 
                 
             The toxin neutralization test and Elisa was correlated by statistical 
methods 
     12 guinea pigs sera by TN should be more than 0.5 IU/ml geometric mean of 
titers detected by ELISA is 0.531 IU after 6 weeks of immunization this shows 
that titers were similar then by TN or ELISA.  
            On receiving one dose of sera from guinea pigs on 9
th
 day showed a titer of 
TT ( 1 in 10 ) . 0.0025IU, 0.005IU ON 20
th
 day and 0.01 IU on 30
th
 day. The titers 
of antibodies that could not be detected by TN were detectable by ELISA. After 
30 days i.e. after receipt of 2 doses of   TT the guinea pig sera showed a level of 
0.531 IU by Elisa showing good correlation with antibodies titers by TN. 
             The antibody levels by ELISA valued from 0.45IU t0 0.572IU/ml indicate 
that if values of 9 out of 12 guinea pigs are taken they and all well about 0.5IU/ml  
which is also the level detectable by antibody titration method also the increase in 
antibody titer 1.2 times the minimum level detected amongst the 12 guinea pig 
sera. Further the increasing in titer of antibodies from 9 day to 30 day from 0.0025 
to 0.01IU is well correlating. This detection not possible by TN. This shows the 
levels acceptable by the ELISA methods has been proven. 
      There were  no statically significant difference  between TN test and ELISA 
12 guinea pig serum pools (p>0.11)  
      The sensitivity & specificity of the ELISA test was 100% as proved in this 
study.           
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Fig – 1 
FLOCCULATION APPARATUS 
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Fig – 2 
INJECTION ON GUINEA PIGS 
 
Fig – 3  
GUINEA PIG ON BEDING 
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Fig – 4 
INJECTION ON MICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig – 5 
MICE BEDING 
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Fig – 6 
ANTIGEN COATED ELISA PLATE 
 
 
 
Fig – 7 
SAMPLE ADDED ELISA PLATE 
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Fig – 8 
CONJUGATED ADDED ELISA PLATE 
 
 
 
Fig – 9 
SUBSTRATE ADDED ELISA PLATE 
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Fig – 10 
STOP SOLUTION ADDED ELISA PLATE 
Conclusion 
 78 
CONCLUSION 
 The results of this project affirm the previous observations that in vitro 
system of assay like ELISA are more quick, sensitive, cost effective, appropriate.  
Further quantifications of  antibodies is an added advantage. 
The findings that the reduction of animals used for potency of TT when 
compared to biological assay contributes to the advantages of using ELISA as a 
routine to assess potency of TT.  A good correlation can be seen between titers of 
antibodies in neutralization toxin test and ELISA. 
Tetanus toxoid is one of the most used immunogens available to protect 
against tetanus. 
1) A considerable reduction and retirement of the use of animals can be achieved 
by introduction of ELISA as a routine for potency of tetanus toxoid. 
2) Substantial reduction of number of mice and quantitative data generated 
boosts up the image of in vitro assay.  
3) ELISA is easy to perform, sensitive, highly reproducible and require only 
small quantities of sera and time saving and objective.  
From the study it was concluded that ELISA standardization done by me in 
the department of biological control (King Institute) is a promoting  alternative to the 
biological potency assay of tetanus toxoid. Rapid technique in the  based on 
application of ELISA. eg : Immuno comb  can be standardized in future  
Therefore the vaccine formulation did not influence the correlation between 
TN and ELISA titers of immunized guinea pig sera. Other workers have also reported 
good correlations between TN and ELISA titers of human sera.
3
 Simonsen et al. 
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found good correlation between ELISA and TN titers of sera from vaccinated human 
populations but no correlation with sera from persons having an incomplete 
vaccination history. 
Our findings of a discrepancy between ELISA and TN titers of immunized 
animals early during the course of immunization have implications on the studies 
where antibody levels are measured by ELISA only.  Therefore, we suggest that the 
ELISA titers of sera from immunized guinea pig or mice should be interpreted 
cautiously up to 6 weeks after a single immunization when the results are expressed as 
titers in weight units (µg/ml) or EAU/ml determined against a hyper-immune serum.  
To overcome the problem of discrepancies between ELISA and TN titers, one 
possibility may be the use of an ELISA reference serum (calibrated by TN test) with 
similar affinity antibodies or similar immunization status as the test serum. 
 
Bibliography 
 
80 
BIBLIOGRAPHY 
1) K. W. Newell, D. R. Leblanc, G. Edsall, L. Levine, H. Christensen, M. H. 
Montouri, & N. Ramirez. The Serological Assessment of a Tetanus Toxoid Field 
Trial  Bull World health organization  1971,45,773 – 785 
2) Indian pharmacopoeia 2007, Volume-3, 1992-1997, Tetanus Vaccine (Adsorbed).   
3) O.Simonsen, C.Schout and I.Heron. Modification of the ELISA for the estimation 
of tetanus antitoxin in human sera.J Biol stand (1987) 15, 143 – 157. 
4) O.Simonsen, M.W. Bentzon  and I. Iterun . Elisa for the rountine determination of 
antitoxic immunity to tetanus, J.Biol  1986, stand 14 – 23- 239. 
5) Moira E.Melville – Smith ,  Valeric A.Seagracft and Johanan T.Watkins . A 
comparison of enzyme linked immunosorbent assay (ELISA) with the toxin 
neutralization test in mice as a method for the estimation of tetanus antitoxin in 
human sera. J.Biol stand 1983, 11 137-144. 
6) L.Pitzurra, F.Bistoni, M.Pitzurra, L.Bastianini, S.Peritu, A.Vecchiarelli, 
P.Marconi, Comparison of passive hemagglutination with Turkey Erythrocyte 
Assay, Enzyme linked immunoserbent assay and counter immunoelectrophonesis 
assay for serological Evaluation of Tetanus immunity; J.clin microbial 1983; 17: 
432 – 435. 
 
Bibliography 
 
81 
7) Nilay Cophi, Berrin Egen, Aysegal Gozalan, Kikuku Muyamora, Iwao Yoshida. 
Oemet Kuitoglu, Nuvido Oztuvu Oogan, Godkhan Asacan. Ahmet Unal Setsuji 
Ishida, and Motohide Takahashi. Tetanus Antibody Assay combining In-house 
ELISA and particle agglutination test and its serosurvey application in a province 
in turkey Jpn. J. Infect Dis 2004, 57 : 97 -102. 
8) M.German – Fattal, BiBizzinmi and A.German. mmunity to tetanus : tetanus 
antitoxin and anti BIIB in human sera. J.Biol stand 1989 15, 223-230 
9) R.k.Gupta,  S.C. Maheshwari  and H.Singh. The titration of tetanus antitoxin IV 
studies on the sensitivity and reproducibility of the toxin neutralization test. J.Biol 
stand 1985 : 13, 143- 149. 
10) GGiuliano Gentili, Carlo Pini  and Clelia Collooffi. The use of an 
immunoenzymatic assay for the estimation of tetanus antitoxin in human sera 
indirect haemagglutination J.Biol stand 1985 : 13, 53 – 59 
11) M.Pitzurra, E.Bistioni, L.Pitzurra, S.P.Marconi. Use of turkey red blood cells in 
the passive haemagglutination test for studying tetanus immunity. Bullet in of the 
world health organization, 61(2) : 331 -338 (1983). 
12) R.K.Gupta, S.C. Maheshwar  and H.Singh. The titration of tetanus antitoxin III. A 
comparative evaluation of indirect haemagglutination and toxin neutralization 
titres of human sera. J.Biol Stand 1984 : 12, 145 – 149. 
13) I..Greenberg, Ph.D. International Standard For Tetanus Toxoid. Bull World health 
organization 1953 : 9,837 – 842. 
Bibliography 
 
82 
14) R.K.Gupta, S.C. Maheshwar  and H.Singh .The titration of tetanus antitoxin II. A 
comparative evaluation of indirect haemagglutination and toxin neutralization  
tests .J.Biol Stand 1983 : 11,137 – 143. 
15) C.F.M. Hendriksen,  J.W.v.d. Gun,  j. Nagel  J.G.Kreeftenberg The toxin binding 
inhibition test as a reliable in vitro alternative to the toxin neutralization test in 
mice for the estimation of tetanus antitoxin in human sera. J.Biol.Stand 1988 : 16, 
287 – 297. 
16) W.J. Herbert. A Study of factors Influencing the Sensitivity to Antibody of 
Tanned, Ovalbumin – Coated, Formalinized Sheep Red Cells Immunology, 1967 : 
13, 459 – 468. 
17) Arthur A.Hirata and Michael W.Brandriss. Passive Hemagglutination Procedures 
for Protein And Polysaccharide Antigens Using jErythrocytes Stabilized By 
Aldehydes.The Journal Of Immunology : Vol 100, No. 3, 1968, 641 – 646. 
18) D.D.Ourth & A .B.Macdonald. Neutralization of tetanus toxin by human and 
rabbit immunoglobulin classes and subunits. Immunology 1977 : 33 : 807 to 815. 
19) Malati Keskar, Maya Natu and M.B. Borkar. Comparison between 
haemagglutination and toxin neutralization for estimation of tetanus antibodies. 
Indian J.Med Res 73, Jan 1981, pp 74 – 76. 
20) E.R. Gold and H.H.Fudenberg. Chromic Choloride: A Coupling Reagent For 
Passive heamogglutination Reactions. The journal of Immunology 1967 vol.99, 
No. 5, 859 – 866. 
Bibliography 
 
83 
21) H.Cohen, M.D., J.D. van Ramshorst,  Ph.D., A.Tasman, Ph.D. Consistency in 
Potency Assay of Tetanus Toxoid In Mice. Bull World health organization 
1959,20, 1133- 1150. 
22) R.Maclennan, F.D. Schofield, Margeret Pittman, M.Carolyn Hardegree, & 
Michael F. Barile. Immunization Against Neonatal Tetanus in New Guinea. Bull 
World health organization 1965, 32, 683- 697. 
23) S.T.Chen, G.Edsall M.M.Peel, & T.A. Sinnathuray Timing of antenatal tetanus 
immunization for effective protection of the neonate. Bull World health 
organization1983, 61(1): 159 – 165. 
24) Margaret M.Peel. Measurement of tetanus antitoxin I. Indirect 
haemagglutination* 1980, Vol 8, 177 – 189. 
25) Inmaculada Esparza and Thomas Kissel. Parameters affecting the 
immunogenicity of microencapsulated tetanus toxoid. Vaccine 1992 Vol : 10, 714 
– 720. 
26)  M.Carolyn Hardegree Michael F. Barile, Margaret Pittman, F. D. Schofield, R. 
Maclennan, & a. Kelly. Immunization Against Neonatal Tetanus in New Guinea 
Bull world health organization 1970, 43, 439 – 451. 
27) Michael F. Barile, M.Carolyn Hardegree & Margaret Pittman. Immunization 
Against Neonatal Tetanus in New Guinea. Bull world health organization 1970, 
43, 453 – 459. 
Bibliography 
 
84 
28) M.carolyn Hardegree, Michael F. Barile, Margaret pittman, Clifford J.Maloney, 
Frank Schofield, & Robert Maclennan Immunization Against Neonatal Tetanus in 
New Guinea. Bull World health organization 1970, 43, 461 – 468. 
29) Giuliano Gengili, Carlo Pini and Clelia Collotti. The use for an immunoenzymatic 
assay for the estimation of tetanus antitoxin in human sera : a comparison with 
seroneutralization and indirect haemagglutination*. J.Biol Stand 1985, 13, 53 – 
59. 
30) Rajesh K.Gupta and George R. Siber Comparison of Adjuvant Activities of 
Aluminium Phosphate, Calcium Phosphate and Stearyl Tyrosine for Tetanus 
Toxoid. Bioliogicals 1994, 22, 53 – 63. 
31) Rajesh K.Gupta, Suzanne Higham, Chander K.Gupta, Bradford Rost and George 
R.Siber. Suitability of the vero cell method for titration of diphtheria antitoxin in 
the united states potency test for diphtheria toxoid Biologicals 1994, 22, 65 – 72. 
32) G.Gentili, C. Pini, and  C . Collotti.. The  determination of the potency of human 
tetanus immnuogolobulins by an enzyme-linked immunosorbent assay* J. Biol 
Stand 1984,12,167—173 
33) M.German-Fattal, B. Bizzini and A. German. Immunity to tetanus: tetanus 
antitoxin and anti-BIIb in human sera J. Biol Stand 1987, 15, 223           - 230 
34) J. D. Van Ramshorst. Titration of Diphtheria and Tetanus Antitoxins in Sera of 
Low Titre  Bull World health organization  1971,45,213 – 218 
Bibliography 
 
85 
35) B. Bycenko, E. Grin, K. I. Matveev, B. Cvjetanovic, E. A. Vorst, & M. 
Stroganova.  The level of Tetanus immunity in the population of villages in 
Bosnia and Herzegovina  Bull World health organization  1971,45,431 – 443 
36) http:// en.wikipedia.org/wiki/ELISA 
37) Indian pharmacopocia 1996, volume –II , A – 33, Appendix  - 2.9 
38) www.rxlist.com/tetanus-toxoid - adsorbed - drug. 
 
 
 
 
